Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis

Table 2

Short-term (28/90 days) survival rates for patients treated with lamivudine vs entecavir or patients with noncirrhotic HBV-ACLF vs cirrhotic HBV-ACLF.

Nucleos(t)ide analogues	28-day survival rate			90-day survival rate
	SMT	ALSS	Overall	SMT	ALSS	Overall
Lamivudine	61.3% (95/155)	64.1% (84/131)	62.6% (179/286)	41.9% (65/155)	49.6% (65/131)	45.5 (130/286)
Entecavir	58.1% (90/155)	77.1% (121/157)	67.6% (211/312)	45.8% (71/155)	62.4% (98/157)	54.2% (169/312)
value	0.563	0.016	0.794	0.492	0.029	0.033
Noncirrhotic HBV-ACLF	60.4% (116/192)	67.0% (120/179)	63.6% (236/371)	45.3% (87/192)	54.2% (97/179)	49.6% (184/371)
Cirrhotic HBV-ACLF	58.5% (69/118)	64.9% (85/131)	61.8% (154/249)	41.5% (49/118)	50.4% (66/131)	46.2% (115/249)
value	0.735	0.692	0.656	0.514	0.507	0.405